EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment

Parker Cordial, Ian D Bentley, Jeffrey C Horowitz iD, Kevin Ho iD

Respirology Case Reports · 2024-09 · 12 (9)

DOI: 10.1002/rcr2.70022 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Respirology Case Reports, online erschienen am 08.09.2024. Verfasst von Parker Cordial und 3 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine The Ohio State University Wexner Medical Center Columbus Ohio USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICI) are increasingly utilized as first‐line treatment for many solid tumour malignancies. One downside of ICI therapy is autoimmune‐mediated organ inflammation, or immune‐related adverse events (irAE). ICI‐related pneumonitis, or non‐infectious inflammation of the lung, is a well‐described irAE. While guidelines surrounding ICI‐related pneumonitis are well established, other ICI‐related pulmonary toxicities, including reactive airways disease, are rarely described in the literature. Here, we present a series of patients without pre‐existing COPD or asthma who developed reactive airways disease with peripheral eosinophilia after ICI therapy and without radiographic evidence of pneumonitis. The patients were treated with typical therapies for reactive airways disease, including– inhaled steroids, bronchodilators, systemic steroids, and in one instance, dupilumab. All experienced symptomatic improvement with these therapies, enabling some of the patients to continue receiving ICI therapy.

Schlagwörter

Stichwörter der Autor:innen

dupilumabeosinophiliaimmune checkpoint inhibitorimmune‐related adverse eventreactive airways disease

Autor:innen und Institutionen

  • Internal Medicine The Ohio State University Wexner Medical Center Columbus Ohio USA.
  • Division of Pulmonary, Critical Care and Sleep Medicine The Ohio State University Wexner Medical Center Columbus Ohio USA.
  • Dorothy M. Davis Heart and Lung Research Institute The Ohio State Wexner Medical Center Columbus Ohio USA.

ORCID-Profile: Jeffrey C Horowitz, Kevin Ho

Zitieren

APA

Cordial, P., Bentley, I. D., Horowitz, J. C., & Ho, K. (2024). Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment. Respirology Case Reports, 12(9). https://doi.org/10.1002/rcr2.70022

Vancouver

Cordial P, Bentley ID, Horowitz JC, Ho K. Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment. Respirology Case Reports. 2024;12(9). doi:10.1002/rcr2.70022

BibTeX
@article{Cordial2024,
  author = {Cordial, Parker and Bentley, Ian D and Horowitz, Jeffrey C and Ho, Kevin},
  title = {Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment},
  journal = {Respirology Case Reports},
  year = {2024},
  volume = {12},
  number = {9},
  doi = {10.1002/rcr2.70022}
}
Kostenlos starten →